Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03292874 Active, not recruiting - Prostate Cancer Clinical Trials

High Resolution MRI Study for Prostate Cancer

Start date: September 13, 2017
Phase: N/A
Study type: Interventional

This high resolution MRI (hrMRI), along with stand MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance. Changes in lesion size and ADC values will be assessed on the serial studies. This study evaluates the hypothesis that hrMRI will detect changes that sMRI cannot detect and that these changes will correlate with prostate cancer progression as determined on prostate biopsy.

NCT ID: NCT03209492 Active, not recruiting - Prostate Cancer Clinical Trials

Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"

Start date: April 1, 2016
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the safety in patients with prostate cancer receiving the drug in the routine clinical setting.

NCT ID: NCT03201380 Active, not recruiting - Prostate Cancer Clinical Trials

Evaluation of the Practice of the TEP Choline at Patients With Prostate Cancer

TEPCholine
Start date: November 1, 2014
Phase: N/A
Study type: Observational

The prostate cancer is a heterogeneous disease the care of which varies according to the status: localized, locally advanced, or in recurrence after local or metastatic treatment. The precise evaluation of the degree of extension of the disease is thus essential because it is going to allow to adapt at best the therapeutic strategy. Contrary to the abdomino-pelvic scanning and to the osseous scintigraphy which(who) are a member(part) of the balance assessment of standard extension of the prostate cancer, the place of the Tomography with broadcast of Positrons to scan (TEP scan) in Choline in the management of patients affected by prostate cancer is not clearly defined in the national and European recommendations. The current marketing authorization ( AMM) is the research for bones localizations in the prostatic cancers at high risk. It indeed seems that this examination is more successful than the standard radiological examinations (bone scintigraphy and abdomino-pelvic scanning) in the detection of the bone metastatic hurts, with a sensibility of about 100 % and a precision of the order of 93 % according to certain studies. The recent data of the literature suggest a quite particular interest at the patients in situation of biochemical recurrence in terms of localization of (or) tumoral site (s). THE AMM however not specifying if this examination has to be made within the framework of the initial balance sheet of extension, at the time of the biochemical second offense or at the known metastatic stage, there is a big variability of the practices according to the centers. The current indications being very ill-assorted, he is interesting being able to estimate the heterogeneousness of the practices of way multicentre, by leading a study observationally retrospective in region Provence-Alpes-Côte d'Azur (PACA).

NCT ID: NCT03199872 Active, not recruiting - Prostate Cancer Clinical Trials

RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

Start date: March 30, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The study will evaluate safety and immunological response to RhoC peptide vaccine in patients with prostate cancer

NCT ID: NCT03162003 Active, not recruiting - Prostate Cancer Clinical Trials

Irish Programme for Stratified Prostate Cancer Therapy

iPROSPECT
Start date: February 2015
Phase: N/A
Study type: Observational

The purpose of the trial is to investigate new clinical tests that could predict what treatments work best for certain patients with advanced prostate cancer by identifying markers and indicators present in blood and tissue which correlate with treatment response.

NCT ID: NCT03149185 Active, not recruiting - Prostate Cancer Clinical Trials

Technology Based Psychosocial Intervention for Symptom Management and HRQOL in Men Living With Advanced Prostate Cancer

PC-CHIP
Start date: May 25, 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effects of various factors such as emotions, stress, stress management techniques (for example relaxation and coping techniques), and health information on quality of life, distress, depression, coping, and physical health in men diagnosed with advanced prostate cancer. We also evaluate the effectiveness of a 10-week group-based internet delivered psychosocial intervention. Primary outcomes are symptom burden (e.g., urinary function, fatigue, pain) and HRQOL (e.g., general, physical & social functioning). Participation in this study includes three face-to-face assessments: baseline (at the beginning of the research study), 6-month follow-up, and 12-month follow-up. The 6- and 12-month follow-up interviews are conducted after the participant has completed the 10-week group intervention. Participants are randomized into either an intervention group (targets stress management skills - relaxation, coping) or a control group (health information and health promotion strategies - benefits of proper nutrition and treatment compliance). Both groups meet for 10 consecutive weeks through an internet video conferencing platform. At the baseline, 6- and 12-month follow-ups, we collect blood and saliva samples. The blood samples go through a three-day process in which we extract and store serum, plasma, and cells for further analysis and gather proliferation data. We use the saliva to measure the cortisol diurnal rhythm.

NCT ID: NCT03075735 Active, not recruiting - Prostate Cancer Clinical Trials

Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC)

Start date: January 15, 2013
Phase: N/A
Study type: Observational [Patient Registry]

PROREPAIR is a prospective multicenter observational cohort study of unselected patients with metastatic Castration Resistant Prostate Cancer (mCRPC) with unknown germline mutational status at study entry and who are candidates to start 1st line treatment with any approved survival-prolonging agent. The study aims to evaluate the impact of aberrations in DNA-repair genes,(BRCA1, BRCA2, ATM and PALB2 and other genes) on cause-specific survival from the diagnosis of the metastatic castration resistant status and other outcomes.

NCT ID: NCT03035487 Active, not recruiting - Prostate Cancer Clinical Trials

Urology of Virginia Case Series

Start date: December 2016
Phase: N/A
Study type: Interventional

The investigational protocol describes a small case series designed to compare three imaging modalities for use in visualizing prostate cancer. The three modalities to be tested are: transrectal micro-ultrasound , and conventional resolution transrectal ultrasound (LR-TRUS) (both as implemented on ExactVu, the multi-frequency novel micro-ultrasound system under investigation), and multi-parametric MRI (mpMRI). These modalities will be used for guiding systematic (standard, random, extended sextant) plus image-guided targeted prostate biopsies among men with known cancer and an indication for prostate biopsy. In the case of mpMRI, biopsy will be performed under micro-ultrasound guidance with the radiology report used for targeting.

NCT ID: NCT02981797 Active, not recruiting - Prostate Cancer Clinical Trials

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223

Start date: March 5, 2015
Phase: N/A
Study type: Observational

This is a prospective biomarker study on prostate cancer patients receiving Radium 223 as standard of care. Participants will take part in this research study because they have chosen Radium 223 treatment for their prostate cancer that has spread to the bone and causing pain. Investigators want to find out if a blood test performed before and after the Radium 223 treatment will help to understand how prostate cancer cells react to this therapy. In this pilot study, researchers want to find out if Radium 223 given as part of standard treatment for prostate cancer can decrease the number of circulating prostate cancer cells. Radium 223 kills prostate cancer cells by damaging their DNA. Other than looking at the changes in the number of circulating prostate cancer cells before and after Radium 223, researchers would also like to look at the changes in a DNA damage marker, called gamma H2AX, in the circulating prostate cancer cells before and after treatment with Radium 223. Assessing the DNA damage marker gamma H2AX is investigational. It is performed in the same tube of blood that is used for assessing the changes in the number of circulating prostate cancer cells.

NCT ID: NCT02966509 Active, not recruiting - Prostate Cancer Clinical Trials

Engagement of Patients With Advanced Cancer

EPAC
Start date: August 2013
Phase: N/A
Study type: Interventional

The Engagement of Patients with Advanced Cancer is an intervention that utilizes well-trained lay health coaches to engage patients and their families in goals of care and shared decision-making after a diagnosis of advanced cancer. Although lay health workers have never been tested in this role, we hypothesize that lay health workers can feasibly improve goals of care documentation and help to reduce unwanted healthcare utilization at the end of life for Veterans diagnosed with new advanced stages of cancer and those diagnosed with recurrent disease.